Medicare to Cover GLP-1 Weight-Loss Drugs Starting July 1
Eligible Medicare beneficiaries can access GLP-1 weight-loss medications for $50/month beginning July 1, but experts urge awareness of side effects.
For the first time, millions of older Americans enrolled in Medicare will gain access to GLP-1 weight-loss drugs beginning July 1, with out-of-pocket costs capped at $50 per month for those who qualify. The landmark coverage shift marks a major expansion of benefits for seniors who have long been excluded from prescription weight-loss treatments under the federal insurance program.
The $50 monthly cap represents a significant reduction in cost compared to the retail price of GLP-1 medications, which can run into hundreds or even thousands of dollars without insurance. Beneficiaries will need to meet specific eligibility requirements to take advantage of the new coverage, underscoring the importance of consulting with a physician or Medicare plan representative before assuming access.
Read more Social Security Overpayment Dispute: Can They Cut Your Benefits? →
While the financial barrier is lower, health experts are urging enrollees to carefully weigh the known side effects associated with GLP-1 drugs. Among the most notable concerns is muscle loss, which can be particularly consequential for older adults who are already at elevated risk for sarcopenia and related mobility issues. Patients are advised to discuss strategies such as increased protein intake and resistance exercise with their doctors to help offset that risk.
The rollout comes as GLP-1 drugs like semaglutide have reshaped the obesity treatment landscape across the United States, generating enormous demand among patients and intense scrutiny from policymakers over long-term costs to public health programs. Medicare's decision to cover these medications for weight loss — not just for diabetes management — signals a broader recognition of obesity as a serious, treatable condition deserving federal support.
Continue reading at MarketWatch.com
